Quality Systems – Page 39

Periodic report inconsistencies during inspection – how to strengthen benefit–risk documentation

Investigating Periodic Report Inconsistencies During Inspection: Enhancing Benefit–Risk Documentation In the highly regulated pharmaceutical environment, the integrity of periodic reports is crucial. Inconsistencies during inspections, particularly related to benefit-risk documentation,…

Artwork change error during scale-up – CAPA and control strategy

“`html Addressing Artwork Change Errors During Scale-Up: Investigation Insights and Control Strategies In the highly regulated pharmaceutical industry, artwork change errors during scale-up can lead to significant compliance issues and…

Case processing backlog during inspection – regulatory enforcement risk and mitigation

Addressing Case Processing Backlogs During Regulatory Inspections During regulatory inspections, the timely processing of cases is crucial for demonstrating compliance and avoiding enforcement actions. However, organizations often experience a backlog…

Extractables and leachables concern during supplier change – how to prevent recall triggers

Managing Extractables and Leachables Concerns During Supplier Change to Mitigate Recall Risks The pharmaceutical industry continually seeks to optimize its supply chain. However, changing suppliers poses inherent risks, particularly regarding…

Periodic report inconsistencies during inspection – CAPA for PV system weaknesses

Addressing Inconsistencies in Periodic Reports During Regulatory Inspections In the highly regulated environment of pharmaceutical development and manufacturing, the accuracy and reliability of periodic reports are crucial. Inconsistencies in these…

Material specification drift during supplier change – CAPA and control strategy

Understanding Material Specification Changes During Supplier Transitions: Investigation and Control Strategies Material specification drift can pose significant risks during supplier changes in pharmaceutical manufacturing. This article discusses how to effectively…

Safety signal escalation delay during post-marketing surveillance – how to strengthen benefit–risk documentation

Addressing Delays in Safety Signal Escalation During Post-Marketing Surveillance In the pharmaceutical industry, the timely identification and escalation of safety signals during post-marketing surveillance are critical for maintaining patient safety…

Supplier qualification gap during scale-up – CAPA and control strategy

Addressing Supplier Qualification Gaps During Scale-Up: A Comprehensive Investigation Approach In pharmaceutical manufacturing, the transition from development to scale-up is a critical juncture where supplier qualification often reveals gaps that…

Risk management plan gaps during signal review – how to strengthen benefit–risk documentation

Addressing Gaps in Risk Management Plans During Signal Review to Enhance Benefit-Risk Documentation Gaps in risk management plans during signal reviews can jeopardize product safety assessments, produce compliance issues, and…

Supplier qualification gap during supplier change – how to prevent recall triggers

Addressing the Gap in Supplier Qualification During Changes to Prevent Recall Triggers Supplier qualification gaps can be a significant risk in pharmaceutical manufacturing, especially during a supplier change. This can…

Safety signal escalation delay during audit response – how to strengthen benefit–risk documentation

Addressing Delays in Safety Signal Escalation During Audit Responses: Strategies for Improvement The pharmaceutical industry continually strives to maintain robust benefit-risk documentation and ensure compliance with regulatory expectations. However, a…

Extractables and leachables concern during inspection readiness – inspection evidence expectations

Understanding Extractables and Leachables Concerns for Regulatory Inspections As regulatory inspections become more stringent, extractables and leachables (E&L) concerns have gained significant attention in the pharmaceutical industry. These substances can…